Follicum receives LUDC post-doc funding for novel diabetes peptide mode of action research

June 13, 2019

Follicum receives LUDC post-doc funding for novel diabetes peptide mode of action research

Follicum AB (“Follicum” or “The Company”), a biotechnology company developing new peptide drugs in two areas, hair loss and diabetes, reports today that Dr. Chrysostomi Gialeli has been recruited to a full-time postdoctoral position for 2 years to further investigate the function and mechanism of action of Follicum’s various peptides. The Postdoc position is 100% financed by the LUDC IRC consortium.

As previously reported, Follicum participates in a large diabetes consortium, LUDC-IRC, which is led from Lund University. LUDC-IRC has received SEK 100 million from the Swedish Foundation for Strategic Research. The consortium’s international council has chosen to finance 5 out of 11 possible postdoc projects that will further advance the research. The purpose of one of the selected projects is to conduct research focusing on Follicum’s peptides and how these interact with the body’s cells to achieve the effects in diabetes that have been previously demonstrated. The research will increase knowledge on how Follicum’s peptides funcion in diabetes. Dr. Gialeli, who is just finishing a post-doc position at Lund University, has extensive experience from research in cellular interactions and signaling mechanisms. She has published more than 27 articles, book chapters or review articles.

CEO Jan Alenfall comments:
“We are very pleased to welcome Chrysostomi Gialeli to the LUDC IRC Consortium. Gaining access to her vast expertise in the study of biological mechanisms of action will be particularly valuable and we expect that her research will contribute to the development and acceleration of the diabetes project. Her work is expected to be completed within 2021. ”

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97

About Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014.

About Lund University Diabetes Center (LUDC)
Lund University Diabetes Center, LUDC, is a consortium of research groups at Lund University that focuses on research on the pathogenesis and treatment of diabetes mellitus.

Open Press release